Used to treat heart issues as well as hyperactive thyroid conditions, it is also a viable tool in weight loss
understanding your genetic profile can support conversations with your provider about which peptide therapies align with your physiology
However, the only reliable safety data on GSH are of sporadic use during chemotherapy cycles, for a few weeks at most
Understanding the science behind each format helps guide more effective product development
Here are some key findings: Within six months of starting GLP-1 therapy, the rate of hypotensive events increased from 8.7% to 10.2% The increased risk remained significant at 12 months, with hypotensive events rising from 13.6% to 14.3% Adults age 65 and older accounted for 53% of hypotensive events despite representing 37% of the study population Patients with Type 2 diabetes made up 75% of those experiencing hypotensive episodes but only 63% of the overall cohort In secondary analyses, the scientists found that weight loss alone did not explain the increased risk, suggesting other mechanisms of action may be at play Northwestern Now posed five questions to the study senior author Dr
And in the latest survey posted by the International Foundation of Employee Benefit Plans in May, 55% of employers said they provide coverage of GLP-1s for diabetes only, while only 36% provide coverage for both diabetes and weight loss